Bluejay Diagnostics Stock Set to Reverse Split on Thursday, June 20th (NASDAQ:BJDX)

Shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) are scheduled to reverse split on Thursday, June 20th. The 1-8 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, June 20th.

Bluejay Diagnostics Trading Down 20.4 %

Shares of NASDAQ BJDX opened at $0.41 on Tuesday. The company has a fifty day moving average price of $0.54 and a 200 day moving average price of $1.04. Bluejay Diagnostics has a 1-year low of $0.34 and a 1-year high of $13.98. The firm has a market cap of $1.09 million, a PE ratio of -0.05 and a beta of 1.06.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, March 28th. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($1.10).

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Sabby Management LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 21,221 shares of the company’s stock, valued at approximately $92,000. Sabby Management LLC owned about 1.71% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.